biotech / news / / NPR
The study is the largest and longest to evaluate a gene therapy for hearing loss.
Gene therapy restored hearing to about 90% of DFNB9 patients in a 42-person trial.
KEY POINTS
- Patients regained hearing within weeks, with improvements lasting over two years in some cases.
- This study is the largest and longest to date evaluating gene therapy for genetic hearing loss.
- Regeneron Pharmaceuticals' gene therapy could soon be the first FDA-approved treatment for deafness.
- Success is prompting exploration of gene therapy for both rare and more common types of hearing loss.
COMPANIES
Summarized by Newsio from NPR. How we summarize →